Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells

References

• Bergman PJ. Cancer immunotherapies. Vet Clin North Am Small Anim Pract. 2019;49:881–902. doi:10.1016/j.cvsm.2019.04.01031186125
   PubMed Web of Science ®Google Scholar
• Scheetz L, Park KS, Li Q, et al. Engineering patient-specific cancer immunotherapies. Nat Biomed Eng. 2019;3:768–782. doi:10.1038/s41551-019-0436-x31406259
   PubMed Web of Science ®Google Scholar
• Yoo TK, Chae BJ, Kim SJ, et al. Identifying long-term survivors among metastatic breast cancer patients undergoing primary tumor surgery. Breast Cancer Res Treat. 2017;165(1):109–118. doi:10.1007/s10549-017-4309-228573447
   PubMed Web of Science ®Google Scholar
• Wargo JA, Reuben A, Cooper ZA, Oh KS, Sullivan RJ. Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy. Semin Oncol. 2015;42(4):601–616. doi:10.1053/j.seminoncol.2015.05.00726320064
   PubMed Web of Science ®Google Scholar
• da Silva JL, Dos Santos ALS, Nunes NCC, de Moraes Lino da Silva F, Ferreira CGM, de Melo AC. Cancer immunotherapy: the art of targeting the tumor immune microenvironment. Cancer Chemother Pharmacol. 2019;84:227–240. doi:10.1007/s00280-019-03894-331240384
   PubMed Web of Science ®Google Scholar
• Lopes A, Vandermeulen G, Preat V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res. 2019;38(1):146. doi:10.1186/s13046-019-1154-730953535
   PubMed Web of Science ®Google Scholar
• McNeel DG. Therapeutic cancer vaccines: how much closer are we? BioDrugs. 2018;32(1):1–7. doi:10.1007/s40259-017-0257-y29285731
   PubMed Web of Science ®Google Scholar
• Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168–182. doi:10.1038/nri.2017.13129226910
   PubMed Web of Science ®Google Scholar
• Gatti-Mays ME, Redman JM, Collins JM, Bilusic M. Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum Vaccin Immunother. 2017;13(11):2561–2574. doi:10.1080/21645515.2017.136432228857666
   PubMed Web of Science ®Google Scholar
• Song Q, Zhang CD, Wu XH. Therapeutic cancer vaccines: from initial findings to prospects. Immunol Lett. 2018;196:11–21. doi:10.1016/j.imlet.2018.01.01129407608
   PubMed Web of Science ®Google Scholar
• Kartikasari AER, Prakash MD, Cox M, et al. Therapeutic cancer vaccines-T cell responses and epigenetic modulation. Front Immunol. 2018;9:3109. doi:10.3389/fimmu.2018.0310930740111
   PubMed Web of Science ®Google Scholar
• Mougel A, Terme M, Tanchot C. Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade. Front Immunol. 2019;10:467. doi:10.3389/fimmu.2019.0046730923527
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Antón LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol. 1996;157(5):1823–1826.8757297
   PubMed Web of Science ®Google Scholar
• Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008;68(17):6889–6895. doi:10.1158/0008-5472.CAN-08-016118757401
   PubMed Web of Science ®Google Scholar
• Li Y, Wang LX, Pang P, et al. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res. 2011;17(22):7047–7057. doi:10.1158/1078-0432.CCR-11-095122068657
   PubMed Web of Science ®Google Scholar
• Su S, Zhou H, Xue M, et al. Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models. Asian Pac J Cancer Prev. 2013;14(5):3109–3116. doi:10.7314/APJCP.2013.14.5.310923803088
   PubMedGoogle Scholar
• Twitty CG, Jensen SM, Hu HM, Fox BA. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res. 2011;17(20):6467–6481. doi:10.1158/1078-0432.CCR-11-081221810919
   PubMed Web of Science ®Google Scholar
• Xue M, Fan F, Ding L, et al. An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation. J Transl Med. 2014;12:361. doi:10.1186/s12967-014-0361-425526800
   PubMed Web of Science ®Google Scholar
• Yu G, Li Y, Cui Z, et al. Combinational immunotherapy with Allo-DRibble vaccines and Anti-OX40 co-stimulation leads to generation of cross-reactive effector T cells and tumor regression. Sci Rep. 2016;6:37558. doi:10.1038/srep3755827874054
   PubMed Web of Science ®Google Scholar
• Aldarouish M, Wang H, Zhou M, Hu HM, Wang LX. Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine. J Exp Clin Cancer Res. 2015;34:34. doi:10.1186/s13046-015-0156-325886865
   PubMed Web of Science ®Google Scholar
• Zhao J, Pan N, Huang F, et al. Vx3-functionalized alumina nanoparticles assisted enrichment of ubiquitinated proteins from cancer cells for enhanced cancer immunotherapy. Bioconjug Chem. 2018;29(3):786–794. doi:10.1021/acs.bioconjchem.7b0057829382195
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019.
   PubMed Web of Science ®Google Scholar
• Fischer MJ. Amine coupling through EDC/NHS: a practical approach. Methods Mol Biol. 2010;627:55–73.20217613
   PubMedGoogle Scholar
• Wang C, Yan Q, Liu HB, Zhou XH, Xiao SJ. Different EDC/NHS activation mechanisms between PAA and PMAA brushes and the following amidation reactions. Langmuir. 2011;27(19):12058–12068. doi:10.1021/la202267p21853994
   PubMed Web of Science ®Google Scholar
• Sohn YS, Lee YK. Site-directed immobilization of antibody using EDC-NHS-activated protein A on a bimetallic-based surface plasmon resonance chip. J Biomed Opt. 2014;19:5. doi:10.1117/1.JBO.19.5.051209
   Web of Science ®Google Scholar
• Holmes KL, Otten G, Yokoyama WM. Flow cytometry analysis using the Becton Dickinson FACS Calibur. Curr Protoc Immunol. 2002;Chapter 5:Unit 5 4.
   PubMedGoogle Scholar
• Adan A, Alizada G, Kiraz Y, Baran Y, Nalbant A. Flow cytometry: basic principles and applications. Crit Rev Biotechnol. 2017;37(2):163–176. doi:10.3109/07388551.2015.112887626767547
   PubMed Web of Science ®Google Scholar
• Tung JW, Heydari K, Tirouvanziam R, et al. Modern flow cytometry: a practical approach. Clin Lab Med. 2007;27:3. doi:10.1016/j.cll.2007.05.001
   Web of Science ®Google Scholar
• Ren H, Zhao S, Li W, et al. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagosomes vaccine (DRibbles). J Immunother. 2014;37(8):383–393. doi:10.1097/CJI.000000000000005125198526
   PubMed Web of Science ®Google Scholar
• Kostko O, Xu B, Jacobs MI, Ahmed M. Soft X-ray spectroscopy of nanoparticles by velocity map imaging. J Chem Phys. 2017;147(1):013931. doi:10.1063/1.498282228688419
   PubMed Web of Science ®Google Scholar
• Schijns V, Tartour E, Michalek J, Stathopoulos A, Dobrovolskiene NT, Strioga MM. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. Cytotherapy. 2014;16(4):427–439. doi:10.1016/j.jcyt.2013.09.00824280238
   PubMed Web of Science ®Google Scholar
• Khong H, Overwijk WW. Adjuvants for peptide-based cancer vaccines. J Immunother Cancer. 2016;4:56. doi:10.1186/s40425-016-0160-y27660710
   PubMed Web of Science ®Google Scholar
• Dong H, Wen ZF, Chen L, et al. Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells. Int J Nanomedicine. 2018;13:3353–3365. doi:10.2147/IJN.S16409729922056
   PubMed Web of Science ®Google Scholar
• Yi Y, Zhou Z, Shu S, et al. Autophagy-assisted antigen cross-presentation: autophagosome as the argo of shared tumor-specific antigens and DAMPs. Oncoimmunology. 2012;1(6):976–978. doi:10.4161/onci.2005923162777
   PubMed Web of Science ®Google Scholar
• Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol. 2010;22(3):132–143. doi:10.1016/j.smim.2010.02.00420356763
   PubMed Web of Science ®Google Scholar
• Curigliano GSG, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther. 2007;7:1225–1241. doi:10.1586/14737140.7.9.122517892423
   PubMed Web of Science ®Google Scholar
• Satoh E, Naganuma H, Sasaki A, Nagasaka M, Ogata H, Nukui H. Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells. J Neuro-Oncol. 1997;33(3):195–200. doi:10.1023/A:1005791621265
   PubMed Web of Science ®Google Scholar
• Huynh MLN, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta 1 secretion and the resolution of inflammation. J Clin Invest. 2002;109(1):41–50. doi:10.1172/JCI021163811781349
   PubMed Web of Science ®Google Scholar
• Srivatsan S, Patel JM, Bozeman EN, et al. Allogeneic tumor cell vaccines the promise and limitations in clinical trials. Hum Vacc Immunother. 2014;10(1):52–63. doi:10.4161/hv.26568
   PubMed Web of Science ®Google Scholar
• Li H, Li Y, Jiao J, Hu HM. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol. 2011;6(10):645–650. doi:10.1038/nnano.2011.15321926980
   PubMed Web of Science ®Google Scholar
• Banday AH, Jeelani S, Hruby VJ. Cancer vaccine adjuvants–recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol. 2015;37(1):1–11. doi:10.3109/08923973.2014.97196325318595
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin S, Wang XY, Zhu G. Nanovaccines for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(5):e1559. doi:10.1002/wnan.155931172659
   PubMed Web of Science ®Google Scholar
• Saxena M, Bhardwaj N. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Curr Opin Immunol. 2017;47:35–43. doi:10.1016/j.coi.2017.06.00328732279
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38(5):1404–1413. doi:10.1002/(ISSN)1521-414118389478
   PubMed Web of Science ®Google Scholar
• Scimeca M, Urbano N, Bonfiglio R, et al. Novel insights into breast cancer progression and metastasis: a multidisciplinary opportunity to transition from biology to clinical oncology. Biochim Biophys Acta Rev Cancer. 2019;1872(1):138–148. doi:10.1016/j.bbcan.2019.07.00231348975
   PubMed Web of Science ®Google Scholar
• Edechi CA, Ikeogu N, Uzonna JE, Myal Y. Regulation of immunity in breast cancer. Cancers (Basel). 2019;11:8. doi:10.3390/cancers11081080
   Google Scholar
• Bao L, Haque A, Jackson K, et al. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol. 2011;178(2):838–852. doi:10.1016/j.ajpath.2010.10.02921281816
   PubMed Web of Science ®Google Scholar
• Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ. Vaccine therapies for breast cancer. Surg Oncol Clin N Am. 2019;28(3):353–367. doi:10.1016/j.soc.2019.02.00431079793
   PubMed Web of Science ®Google Scholar
• Kaur P, Nagaraja GM, Zheng H, et al. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer. 2012;12:120. doi:10.1186/1471-2407-12-12022452810
   PubMed Web of Science ®Google Scholar
• Sztalmachova M, Gumulec J, Raudenska M, et al. Molecular response of 4T1-induced mouse mammary tumours and healthy tissues to zinc treatment. Int J Oncol. 2015;46(4):1810–1818. doi:10.3892/ijo.2015.288325672434
   PubMed Web of Science ®Google Scholar
• Marshall HT, Djamgoz MBA. Immuno-oncology: emerging targets and combination therapies. Front Oncol. 2018;8:315. doi:10.3389/fonc.2018.0031530191140
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017;5:16. doi:10.1186/s40425-017-0218-528239469
   PubMed Web of Science ®Google Scholar
• Wang YJ, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis. 2018;5(3):194–203. doi:10.1016/j.gendis.2018.05.00330320184
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Anderson R. Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy. Int J Mol Sci. 2019;20:4. doi:10.3390/ijms20040959
   Web of Science ®Google Scholar